CA
CMPX icon

Clearstead Advisors’s Compass Therapeutics CMPX Stock Holding History

Clearstead Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72K Buy
+783
New +$2.31K ﹤0.01% 2531
2025
Q4 		– Sell
-4
Closed -$14 – 2844
2025
Q3 		$14 Buy
+4
New +$13 ﹤0.01% 3038

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Clearstead Advisors's CMPX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 783 shares worth $1.72K. The stake represents ﹤0.01% of the portfolio and ranks #2531 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CMPX as recently as Q3 2025.

Clearstead Advisors first reported a position in CMPX in Q3 2025 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Clearstead Advisors held 783 shares of Compass Therapeutics worth $1.72K as of Q2 2026.
  • Compass Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2531 holding.
  • Clearstead Advisors first reported a position in Compass Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.